Major investment signals keen interest in psychedelics for mental health care
Mental Health Weekly August 26, 2023 DOI: 10.1002/mhw.33764 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Key points | A leading developer of psychedelic drug therapies announced up to $285 million in private placement financing. The company's CEO told MHW the announcement signals important validation of the drug sector's role in mental health treatment. |
Abstract
This month's announcement of up to $285 million in private placement financing for a leading developer of psychedelic drug therapies signals an important validation of this drug sector's role in mental health treatment, the biotechnology company's CEO told MHW last week.